Please assess the completion status of the following clinical trial:

Trial Title: Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this study:~1. You must be at least 18 years of age and not older than 60 years of age~2. You have breast cancer which was confined to the breast and lymph nodes under the arm, and have no evidence of cancer elsewhere~3. You must have had surgical removal of your tumor, and if indicated, radiation therapy must have been completed or planned~4. Your tumor must express estrogen and/or progesterone receptors~5. You must have had a menstrual period within 6 months before starting chemotherapy for your breast cancer.~6. You must have been treated with a chemotherapy regimen that includes cyclophosphamide (Cytoxan). Your menstrual periods must have stopped for at least 8 weeks starting during or after chemotherapy.~Exclusion Criteria:~You are not eligible to participate in this study if:~1. Your ovaries have been surgically removed, treated with radiation therapy, or if you are taking medications (Zoladex™ or Lupron™) to block the function of your ovaries.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- anastrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).